Differential intestinal anti-inflammatory effects of Lactobacillus fermentum and Lactobacillus salivarius in DSS mouse colitis: impact on microRNAs expression and microbiota composition

Molecular Nutrition and Food Research

Volumn 61, Issue 11, 2017, Pages

  Rodríguez Nogales, Alba ^a   Algieri, Francesca ^a   Garrido Mesa, Jose ^a   Vezza, Teresa ^a   Utrilla, M Pilar ^a   Chueca, Natalia ^b   Garcia, Federico ^b   Olivares, Mónica ^c   Rodríguez Cabezas, M Elena ^a   Gálvez, Julio ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c Research Department of Biosearch   (Spain)

Author keywords

DSS mouse colitis; Microbiota; MicroRNA; Probiotic; Pyrosequencing

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; DEXTRAN SULFATE; MICRORNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT;

ANIMAL; BLOOD; C57BL MOUSE; COLITIS; COMPARATIVE STUDY; DIET THERAPY; DYSBIOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOLOGY; INTESTINE FLORA; INTESTINE MUCOSA; LACTOBACILLUS FERMENTUM; LACTOBACILLUS SALIVARIUS; MALE; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PRINCIPAL COMPONENT ANALYSIS; RANDOMIZATION; REGULATORY T LYMPHOCYTE; TH1 TH2 BALANCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; COLITIS; CYTOKINES; DEXTRAN SULFATE; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; INTESTINAL MUCOSA; LACTOBACILLUS FERMENTUM; LACTOBACILLUS SALIVARIUS; MALE; MICE, INBRED C57BL; MICRORNAS; PRINCIPAL COMPONENT ANALYSIS; PROBIOTICS; RANDOM ALLOCATION; T-LYMPHOCYTES, REGULATORY; TH1-TH2 BALANCE;

EID: 85032665087     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201700144     Document Type: Article

References (85)

1. Baumgart, D. C., Sandborn, W. J., Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (London, England) 2007, 369, 1641–1657.
2. Kaser, A., Zeissig, S., Blumberg, R. S., Genes and environment: how will our concepts on the pathophysiology of IBD develop in the future? Dig. Dis. 2010, 28, 395–405.
3. Sartor, R. B., Wu, G. D., Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology 2017, 152, 327–339 e324.
4. Gunther, C., Josenhans, C., Wehkamp, J., Crosstalk between microbiota, pathogens and the innate immune responses. Int. J. Med. Microbiol. 2016, 306, 257–265.
5. Wallace, K. L., Zheng, L. B., Kanazawa, Y., Shih, D. Q., Immunopathology of inflammatory bowel disease. World J. Gastroenterol. 2014, 20, 6–21.
6. Kalla, R., Ventham, N. T., Kennedy, N. A., MicroRNAs: new players in inflammatory bowel disease. Gut 2015, 64, 1008.
7. McKenna, L. B., Schug, J., Vourekas, A., McKenna, J. B. et al., MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 2010, 139, 1654–1664, 1664 e1651.
8. Miska, E. A., How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev. 2005, 15, 563–568.
9. Schickel, R., Boyerinas, B., Park, S. M., Peter, M. E., MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008, 27, 5959–5974.
10. Dalmasso, G., Nguyen, H. T., Yan, Y., Laroui, H. et al., Microbiota modulate host gene expression via microRNAs. PLoS One 2011, 6, e19293.
11. Hu, S., Dong, T. S., Dalal, S. R., Wu, F. et al., The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene expression in human colon cancer. PLoS One 2011, 6, e16221.
12. Xue, X., Cao, A. T., Cao, X., Yao, S. et al., Downregulation of microRNA-107 in intestinal CD11c(+) myeloid cells in response to microbiota and proinflammatory cytokines increases IL-23p19 expression. Eur. J. Immunol. 2014, 44, 673–682.
13. Xiao, C., Rajewsky, K., MicroRNA control in the immune system: basic principles. Cell 2009, 136, 26–36.
14. Chen, W. X., Ren, L. H., Shi, R. H., Implication of miRNAs for inflammatory bowel disease treatment: systematic review. World J. Gastrointest. Pathophysiol. 2014, 5, 63–70.
15. Chapman, C. G., Pekow, J., The emerging role of miRNAs in inflammatory bowel disease: a review. Therap. Adv. Gastroenterol. 2015, 8, 4–22.
16. Xu, X. M., Zhang, H. J., miRNAs as new molecular insights into inflammatory bowel disease: Crucial regulators in autoimmunity and inflammation. World J. Gastroenterol. 2016, 22, 2206–2218.
17. Ye, D., Guo, S., Al-Sadi, R., Ma, T. Y., MicroRNA regulation of intestinal epithelial tight junction permeability. Gastroenterology 2011, 141, 1323–1333.
18. Bian, Z., Li, L., Cui, J., Zhang, H. et al., Role of miR-150-targeting c-Myb in colonic epithelial disruption during dextran sulphate sodium-induced murine experimental colitis and human ulcerative colitis. J. Pathol. 2011, 225, 544–553.
19. Zhao, Y., Ma, T., Chen, W., Chen, Y. et al., MicroRNA-124 promotes intestinal inflammation by targeting Aryl hydrocarbon receptor in Crohn's disease. J. Crohns Colitis 2016, 10, 703–712.
20. Feng, X., Wang, H., Ye, S., Guan, J. et al., Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IkappaBalpha. PloS one 2012, 7, e52782.
21. Singh, U. P., Murphy, A. E., Enos, R. T., Shamran, H. A. et al., miR-155 deficiency protects mice from experimental colitis by reducing T helper type 1/type 17 responses. Immunology 2014, 143, 478–489.
22. Kostic, A. D., Xavier, R. J., Gevers, D., The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014, 146, 1489–1499.
23. Runtsch, M. C., Round, J. L., O'Connell, R. M., MicroRNAs and the regulation of intestinal homeostasis. Front. Genet. 2014, 5, 347.
24. Bernstein, C. N., Spicing up the treatment of mild to moderate ulcerative colitis. Clin. Gastroenterol. Hepatol. 2015, 13, 1450–1452.
25. Dignass, A., Van Assche, G., Lindsay, J. O., Lemann, M. et al., The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010, 4, 28–62.
26. Durchschein, F., Petritsch, W., Hammer, H. F., Diet therapy for inflammatory bowel diseases: the established and the new. World J. Gastroenterol. 2016, 22, 2179–2194.
27. Rossi, R. E., Whyand, T., Murray, C. D., Hamilton, M. I. et al., The role of dietary supplements in inflammatory bowel disease: a systematic review. Eur J Gastroenterol Hepatol 2016, 28, 1357–1364.
28. Claes, I. J., De Keersmaecker, S. C., Vanderleyden, J., Lebeer, S., Lessons from probiotic-host interaction studies in murine models of experimental colitis. Mol. Nutr. Food Res. 2011, 55, 1441–1453.
29. Plaza-Diaz, J., Ruiz-Ojeda, F. J., Vilchez-Padial, L. M., Gil, A., Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients 2017, 9, 555.
30. Arribas, B., Garrido-Mesa, N., Peran, L., Camuesco, D. et al., The immunomodulatory properties of viable Lactobacillus salivarius ssp. salivarius CECT5713 are not restricted to the large intestine. Eur J Nutr 2012, 51, 365–374.
31. Rodriguez-Nogales, A., Algieri, F., Vezza, T., Garrido-Mesa, N. et al., The viability of Lactobacillus fermentum CECT5716 is not essential to exert intestinal anti-inflammatory properties. Food Funct 2015, 6, 1176–1184.
32. Peran, L., Camuesco, D., Comalada, M., Nieto, A. et al., Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J. Gastroenterol. 2005, 11, 5185–5192.
33. Peran, L., Camuesco, D., Comalada, M., Nieto, A. et al., Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. Int. J. Colorectal Dis. 2006, 21, 737–746.
34. Mane, J., Loren, V., Pedrosa, E., Ojanguren, I. et al., Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice. Inflamm. Bowel Dis. 2009, 15, 1155–1163.
35. Rivero-Gutierrez, B., Gamez-Belmonte, R., Suarez, M. D., Lavin, J. L. et al., A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota. Mol. Nutr. Food Res. 2017, 61, 1600622.
36. Peran, L., Sierra, S., Comalada, M., Lara-Villoslada, F. et al., A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br. J. Nutr. 2007, 97, 96–103.
37. Mahler, M., Bristol, I. J., Leiter, E. H., Workman, A. E. et al., Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am. J. Physiol. 1998, 274, G544–G551.
38. Cooper, H. S., Murthy, S. N., Shah, R. S., Sedergran, D. J., Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 1993, 69, 238–249.
39. Bergstrom, K. S., Kissoon-Singh, V., Gibson, D. L., Ma, C. et al., Muc2 protects against lethal infectious colitis by disassociating pathogenic and commensal bacteria from the colonic mucosa. PLoS Pathog. 2010, 6, e1000902.
40. Camuesco, D., Rodriguez-Cabezas, M. E., Garrido-Mesa, N., Cueto-Sola, M. et al., The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br. J. Pharmacol. 2012, 165, 729–740.
41. Garrido-Mesa, J., Algieri, F., Rodriguez-Nogales, A., Utrilla, M. P. et al., A new therapeutic association to manage relapsing experimental colitis: doxycycline plus Saccharomyces boulardii. Pharmacological Res. 2015, 97, 48–63.
42. Garrido-Mesa, N., Utrilla, P., Comalada, M., Zorrilla, P. et al., The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. Biochem. Pharmacol. 2011, 82, 1891–1900.
43. Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K. et al., QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 2010, 7, 335–336.
44. Wang, M., Monaco, M. H., Donovan, S. M., Impact of early gut microbiota on immune and metabolic development and function. Semin Fetal Neonatal Med 2016, 21, 380–387.
45. Joyce, S. A., Gahan, C. G., Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health. Annu Rev Food Sci Technol 2016, 7, 313–333.
46. Shadnoush, M., Hosseini, R. S., Khalilnezhad, A., Navai, L. et al., Effects of probiotics on gut microbiota in patients with inflammatory bowel disease: a double-blind, placebo-controlled clinical trial. Korean J. Gastroenterol. 2015, 65, 215–221.
47. Stephani, J., Radulovic, K., Niess, J. H., Gut microbiota, probiotics and inflammatory bowel disease. Arch. Immunol. Ther. Exp. (Warsz.) 2011, 59, 161–177.
48. Korzenik, J. R., Podolsky, D. K., Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006, 5, 197–209.
49. Camuesco, D., Comalada, M., Rodriguez-Cabezas, M. E., Nieto, A. et al., The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br. J. Pharmacol. 2004, 143, 908–918.
50. Gao, Q., Meijer, M. J., Kubben, F. J., Sier, C. F. et al., Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 2005, 37, 584–592.
51. Koelink, P. J., Overbeek, S. A., Braber, S., Morgan, M. E. et al., Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut 2014, 63, 578–587.
52. Su, L., Shen, L., Clayburgh, D. R., Nalle, S. C. et al., Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009, 136, 551–563.
53. Gersemann, M., Becker, S., Kubler, I., Koslowski, M. et al., Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation 2009, 77, 84–94.
54. McGuckin, M. A., Eri, R., Simms, L. A., Florin, T. H. et al., Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis. 2009, 15, 100–113.
55. Kim, Y. S., Ho, S. B., Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010, 12, 319–330.
56. Kumar, M., Kissoon-Singh, V., Coria, A. L., Moreau, F. et al., Probiotic mixture VSL#3 reduces colonic inflammation and improves intestinal barrier function in Muc2 mucin-deficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2017, 312, G34–G45.
57. Krishnan, M., Penrose, H. M., Shah, N. N., Marchelletta, R. R. et al., VSL#3 probiotic stimulates T-cell protein tyrosine phosphatase-mediated recovery of IFN-gamma-induced intestinal epithelial barrier defects. Inflamm. Bowel Dis. 2016, 22, 2811–2823.
58. Griffiths-Jones, S., Grocock, R. J., van Dongen, S., Bateman, A. et al., miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006, 34, D140–144.
59. Kloosterman, W. P., Plasterk, R. H., The diverse functions of microRNAs in animal development and disease. Dev. Cell 2006, 11, 441–450.
60. Pfeifer, A., Lehmann, H., Pharmacological potential of RNAi–focus on miRNA. Pharmacol. Ther. 2010, 126, 217–227.
61. Archanioti, P., Gazouli, M., Theodoropoulos, G., Vaiopoulou, A. et al., Micro-RNAs as regulators and possible diagnostic bio-markers in inflammatory bowel disease. J Crohns Colitis 2011, 5, 520–524.
62. O'Connell, R. M., Kahn, D., Gibson, W. S., Round, J. L. et al., MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010, 33, 607–619.
63. O'Connell, R. M., Rao, D. S., Chaudhuri, A. A., Baltimore, D., Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010, 10, 111–122.
64. Ambros, V., The functions of animal microRNAs. Nature 2004, 431, 350–355.
65. Androulidaki, A., Iliopoulos, D., Arranz, A., Doxaki, C. et al., The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009, 31, 220–231.
66. Banerjee, A., Schambach, F., DeJong, C. S., Hammond, S. M. et al., Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur. J. Immunol. 2010, 40, 225–231.
67. Fasseu, M., Treton, X., Guichard, C., Pedruzzi, E. et al., Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PloS one 2010, 5, e13160.
68. Haneklaus, M., Gerlic, M., Kurowska-Stolarska, M., Rainey, A. A. et al., Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J. Immunol. 2012, 189, 3795–3799.
69. Starczynowski, D. T., Kuchenbauer, F., Argiropoulos, B., Sung, S. et al., Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat. Med. 2010, 16, 49–58.
70. Pekow, J. R., Dougherty, U., Mustafi, R., Zhu, H. et al., miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes. Inflamm. Bowel Dis. 2012, 18, 94–100.
71. Chivukula, R. R., Shi, G., Acharya, A., Mills, E. W. et al., An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell 2014, 157, 1104–1116.
72. Xu, J., Zhao, J., Evan, G., Xiao, C. et al., Circulating microRNAs: novel biomarkers for cardiovascular diseases. J. Mol. M. 2012, 90, 865–875.
73. Ding, L., Xu, Y., Zhang, W., Deng, Y. et al., MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 2010, 20, 784–793.
74. Zhao, X., Song, H., Zuo, Z., Zhu, Y. et al., Identification of miRNA-miRNA synergistic relationships in colorectal cancer. Int. J. Biol. Macromol. 2013, 55, 98–103.
75. Schaefer, J. S., Montufar-Solis, D., Vigneswaran, N., Klein, J. R., Selective upregulation of microRNA expression in peripheral blood leukocytes in IL-10-/- mice precedes expression in the colon. J. Immunol. 2011, 187, 5834–5841.
76. Giahi, L., Aumueller, E., Elmadfa, I., Haslberger, A. G., Regulation of TLR4, p38 MAPkinase, IkappaB and miRNAs by inactivated strains of lactobacilli in human dendritic cells. Benef Microbes 2012, 3, 91–98.
77. DuPont, A. W., DuPont, H. L., The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 2011, 8, 523–531.
78. Gareau, M. G., Sherman, P. M., Walker, W. A., Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010, 7, 503–514.
79. Frank, D. N., St Amand, A. L., Feldman, R. A., Boedeker, E. C. et al., Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 13780–13785.
80. Walker, A. W., Sanderson, J. D., Churcher, C., Parkes, G. C. et al., High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011, 11, 7.
81. Hartog, A., Belle, F. N., Bastiaans, J., de Graaff, P. et al., A potential role for regulatory T-cells in the amelioration of DSS induced colitis by dietary non-digestible polysaccharides. J. Nutr. Biochem. 2015, 26, 227–233.
82. Machiels, K., Joossens, M., Sabino, J., De Preter, V. et al., A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014, 63, 1275–1283.
83. Smits, L. P., Bouter, K. E., de Vos, W. M., Borody, T. J. et al., Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013, 145, 946–953.
84. Kameyama, K., Nemoto, Y., Kanai, T., Shinohara, T. et al., IL-2 is positively involved in the development of colitogenic CD4+ IL-7R alpha high memory T cells in chronic colitis. Eur. J. Immunol. 2010, 40, 2423–2436.
85. Circu, M. L., Aw, T. Y., Redox biology of the intestine. Free Radic. Res. 2011, 45, 1245–1266.